Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

37.31
+1.042.87%
Post-market: 36.76-0.5500-1.47%16:13 EDT
Volume:691.82K
Turnover:25.78M
Market Cap:2.61B
PE:-12.23
High:38.13
Open:36.27
Low:35.70
Close:36.27
52wk High:38.13
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:1.03
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0508
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.43
PE(LYR):-10.70

Loading ...

Pharvaris Nv - FDA Sets Pdufa Action Date for Deucrictibant Ir Nda as April 23, 2027

THOMSON REUTERS
·
Jul 06

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant Ir for On-demand Treatment of Hereditary Angioedema Attacks

THOMSON REUTERS
·
Jul 06

Pharvaris Chief Early Development Anne Lesage Disposes of Common Shares Worth $2,661,782.82

Reuters
·
Jul 02

Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)

TIPRANKS
·
Jun 30

Pharvaris Chief Medical Officer Lu Peng Disposes of 29,700 Common Shares for $1.02 Million

Reuters
·
Jun 30

Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM

TIPRANKS
·
Jun 26

Pharvaris Shareholders Adopt Dutch Statutory Annual Accounts for Fy2025

Reuters
·
Jun 26

Pharvaris is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 26

Pharvaris price target raised to $46 from $41 at Morgan Stanley

TIPRANKS
·
Jun 25

Pharvaris CMO Lu Peng disposes of 300 shares worth $10,200

Reuters
·
Jun 24

Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction

Simply Wall St.
·
Jun 19

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)

TIPRANKS
·
Jun 16

Pharvaris says Phase 3 RAPIDe-3 trial shows oral deucrictibant cuts median HAE symptom relief time to 1.28 hours

Reuters
·
Jun 15

Pharvaris publishes patient-reported outcomes presentation on clinical evidence in HAE trials

Reuters
·
Jun 12

Pharvaris announces annual shareholder meeting

Reuters
·
Jun 11

A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst

Simply Wall St.
·
Jun 07

The Bull Case For Pharvaris (PHVS) Could Change Following New Deucrictibant Phase 3 Data Disclosures

Simply Wall St.
·
May 31

Pharvaris to present Phase 3 RAPIDe-3 end-of-progression data for oral deucrictibant in hereditary angioedema at EAACI 2026

Reuters
·
May 29

Pharvaris Principal Accounting Officer Anna Nijdam disposes of common shares worth $224,207.69

Reuters
·
May 27

Pharvaris director Elisabeth Bjork disposes 10,000 common shares for $293,166

Reuters
·
May 23